Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2024
0mins
Should l Buy CYCN?
Source: Newsfilter
Company Update: Cyclerion Therapeutics is focusing on leveraging its soluble guanylate cyclase (sGC) stimulator assets to generate revenue and reduce operating expenses, while also seeking new CNS assets to rebuild its pipeline.
Agreements and Financials: The company has amended its license agreement with Akebia for praliciguat, securing $1.75 million upfront, and entered an exclusive license option for olinciguat, while previously selling CNS assets to Tisento Therapeutics for $8 million and equity stake.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CYCN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CYCN
About CYCN
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cyclerion Receives Positive FDA Feedback, Advancing CYC-126 Study
- Positive FDA Feedback: Cyclerion has received encouraging written feedback from the FDA regarding CYC-126, clarifying its clinical development pathway for treatment-resistant depression (TRD), with plans to initiate the Phase 2 proof-of-concept study in the second half of 2026, marking a significant advancement in the company's drug development efforts.
- Personalized Treatment Strategy: CYC-126 integrates real-time electroencephalogram (EEG) feedback with individualized anesthetic dosing, aiming to precisely guide patients to brain states associated with antidepressant effects, addressing the urgent need for new therapies among TRD patients and presenting substantial market potential.
- Clinical Advisory Board Formation: Cyclerion has established a Clinical Advisory Board, appointing five internationally recognized experts in neuropsychiatry and anesthesiology to provide strategic guidance, ensuring that the clinical development of CYC-126 adheres to the highest scientific standards while expanding the company's pipeline in neuropsychiatric diseases.
- Multinational Study Plans: The company has selected a contract research organization to support the execution of the planned multinational study, ensuring the initiation of the Phase 2 study of CYC-126 in the second half of 2026, further solidifying its market position in the treatment of neuropsychiatric disorders.
See More
AZZ Inc Reports Q3 Earnings Beat, Shares Rise 2.1%
- Earnings Beat: AZZ Inc reported adjusted earnings of $1.52 per share for Q3, surpassing market expectations of $1.47, indicating sustained profitability that may attract more investor interest.
- Sales Growth: The company achieved sales of $425.746 million, exceeding expectations of $418.164 million, demonstrating strong market demand and further solidifying its position in the industry.
- Stock Price Surge: In pre-market trading, AZZ Inc shares rose 2.1% to $112.09, reflecting a positive market reaction to its earnings report, which could boost investor confidence in subsequent trading days.
- Optimistic Market Outlook: With improved performance, AZZ Inc is poised to continue attracting investment and enhancing its competitive edge, particularly in the context of the current economic recovery.
See More
Alumis Inc. Shares Surge 132% After Successful Phase 3 Trial Results
- Trial Success: Alumis Inc. achieved all primary and secondary endpoints in its Phase 3 ONWARD1 and ONWARD2 trials for envudeucitinib in moderate-to-severe plaque psoriasis, resulting in a 132% surge in stock price, indicating strong market potential and investor confidence.
- Market Reaction: Following the announcement, shares skyrocketed to $19.30, reflecting a positive investor response to the clinical data, which may attract more institutional investors and further enhance the company's market capitalization.
- Industry Impact: Alumis's success provides a new treatment option in the biopharmaceutical industry, particularly in the psoriasis sector, potentially prompting other companies to increase R&D investments and drive overall industry innovation.
- Future Outlook: With the successful clinical trials, Alumis is expected to accelerate the drug's market entry, likely leading to significant revenue growth while strengthening its position in the highly competitive biopharmaceutical market.
See More
AngioDynamics Surpasses Expectations with $79.4M Sales and Break-Even EPS
- Earnings Beat: AngioDynamics reported an adjusted EPS of $0.00 for Q2, exceeding market expectations of a 10-cent loss, indicating a significant improvement in the company's profitability.
- Sales Growth: The company achieved sales of $79.4 million, surpassing the market forecast of $76.3 million, demonstrating strong product demand and driving overall performance enhancement.
- Positive Market Reaction: Following the earnings release, AngioDynamics' stock received favorable attention from investors, reflecting confidence in its future growth potential, which may further drive stock price appreciation.
- Optimistic Industry Outlook: With the recovery of the medical device sector, AngioDynamics' robust performance could attract more investor interest, strengthening its position in a competitive market.
See More
Cyclerion (CYCN) Enters Exclusive Collaboration with Medsteer to Advance CYC-126 Clinical Trials
- Exclusive Collaboration Agreement: Cyclerion Therapeutics has signed an application-specific exclusive collaboration with Medsteer, aiming to integrate Medsteer's closed-loop anesthetic delivery systems with Cyclerion's CYC-126 program, thereby enhancing clinical development efficiency for treatment-resistant depression.
- Clinical Trial Plans: Cyclerion plans to initiate a Phase 2 Proof of Concept clinical trial for CYC-126 in the second half of 2026, which is expected to provide personalized treatment for approximately 3 million Americans suffering from treatment-resistant depression, significantly improving patient quality of life.
- Positive Market Reaction: Following the announcement of the collaboration, CYCN's stock surged 47.10% in premarket trading to $2.03, reflecting strong market recognition of the collaboration's potential, which may drive future financing and growth for the company.
- Technology Integration Progress: Cyclerion will leverage its neuropsychiatric and clinical development expertise to strengthen the integration with Medsteer's technology, with device integration expected to be completed in 2026, laying a solid foundation for subsequent clinical trials.
See More
Cyclerion Therapeutics Expands Collaboration with Medsteer, Shares Surge 44.2%
- Significant Stock Surge: Cyclerion Therapeutics shares rose 44.2% to $1.99 in pre-market trading, reflecting strong market confidence in the company's expanded strategic collaboration with Medsteer, indicating positive investor sentiment towards future growth prospects.
- Deepening Strategic Collaboration: The partnership with Medsteer aims to advance the closed-loop anesthetic platform CYC-126, which is expected to accelerate the product's market entry, thereby enhancing the company's competitive edge in the anesthesia sector.
- Optimistic Market Outlook: With continuous advancements in anesthetic technology, Cyclerion's new platform is poised to meet the increasing medical demand, further driving revenue growth and strengthening its position in the healthcare industry.
- Increased Investor Confidence: The substantial stock price increase not only reflects market approval of the company's strategic direction but may also attract more investor interest, thereby supporting future financing and expansion efforts.
See More
Cyclerion Receives Positive FDA Feedback, Advancing CYC-126 Study
- Positive FDA Feedback: Cyclerion has received encouraging written feedback from the FDA regarding CYC-126, clarifying its clinical development pathway for treatment-resistant depression (TRD), with plans to initiate the Phase 2 proof-of-concept study in the second half of 2026, marking a significant advancement in the company's drug development efforts.
- Personalized Treatment Strategy: CYC-126 integrates real-time electroencephalogram (EEG) feedback with individualized anesthetic dosing, aiming to precisely guide patients to brain states associated with antidepressant effects, addressing the urgent need for new therapies among TRD patients and presenting substantial market potential.
- Clinical Advisory Board Formation: Cyclerion has established a Clinical Advisory Board, appointing five internationally recognized experts in neuropsychiatry and anesthesiology to provide strategic guidance, ensuring that the clinical development of CYC-126 adheres to the highest scientific standards while expanding the company's pipeline in neuropsychiatric diseases.
- Multinational Study Plans: The company has selected a contract research organization to support the execution of the planned multinational study, ensuring the initiation of the Phase 2 study of CYC-126 in the second half of 2026, further solidifying its market position in the treatment of neuropsychiatric disorders.
See More
AZZ Inc Reports Q3 Earnings Beat, Shares Rise 2.1%
- Earnings Beat: AZZ Inc reported adjusted earnings of $1.52 per share for Q3, surpassing market expectations of $1.47, indicating sustained profitability that may attract more investor interest.
- Sales Growth: The company achieved sales of $425.746 million, exceeding expectations of $418.164 million, demonstrating strong market demand and further solidifying its position in the industry.
- Stock Price Surge: In pre-market trading, AZZ Inc shares rose 2.1% to $112.09, reflecting a positive market reaction to its earnings report, which could boost investor confidence in subsequent trading days.
- Optimistic Market Outlook: With improved performance, AZZ Inc is poised to continue attracting investment and enhancing its competitive edge, particularly in the context of the current economic recovery.
See More
Alumis Inc. Shares Surge 132% After Successful Phase 3 Trial Results
- Trial Success: Alumis Inc. achieved all primary and secondary endpoints in its Phase 3 ONWARD1 and ONWARD2 trials for envudeucitinib in moderate-to-severe plaque psoriasis, resulting in a 132% surge in stock price, indicating strong market potential and investor confidence.
- Market Reaction: Following the announcement, shares skyrocketed to $19.30, reflecting a positive investor response to the clinical data, which may attract more institutional investors and further enhance the company's market capitalization.
- Industry Impact: Alumis's success provides a new treatment option in the biopharmaceutical industry, particularly in the psoriasis sector, potentially prompting other companies to increase R&D investments and drive overall industry innovation.
- Future Outlook: With the successful clinical trials, Alumis is expected to accelerate the drug's market entry, likely leading to significant revenue growth while strengthening its position in the highly competitive biopharmaceutical market.
See More
AngioDynamics Surpasses Expectations with $79.4M Sales and Break-Even EPS
- Earnings Beat: AngioDynamics reported an adjusted EPS of $0.00 for Q2, exceeding market expectations of a 10-cent loss, indicating a significant improvement in the company's profitability.
- Sales Growth: The company achieved sales of $79.4 million, surpassing the market forecast of $76.3 million, demonstrating strong product demand and driving overall performance enhancement.
- Positive Market Reaction: Following the earnings release, AngioDynamics' stock received favorable attention from investors, reflecting confidence in its future growth potential, which may further drive stock price appreciation.
- Optimistic Industry Outlook: With the recovery of the medical device sector, AngioDynamics' robust performance could attract more investor interest, strengthening its position in a competitive market.
See More
Cyclerion (CYCN) Enters Exclusive Collaboration with Medsteer to Advance CYC-126 Clinical Trials
- Exclusive Collaboration Agreement: Cyclerion Therapeutics has signed an application-specific exclusive collaboration with Medsteer, aiming to integrate Medsteer's closed-loop anesthetic delivery systems with Cyclerion's CYC-126 program, thereby enhancing clinical development efficiency for treatment-resistant depression.
- Clinical Trial Plans: Cyclerion plans to initiate a Phase 2 Proof of Concept clinical trial for CYC-126 in the second half of 2026, which is expected to provide personalized treatment for approximately 3 million Americans suffering from treatment-resistant depression, significantly improving patient quality of life.
- Positive Market Reaction: Following the announcement of the collaboration, CYCN's stock surged 47.10% in premarket trading to $2.03, reflecting strong market recognition of the collaboration's potential, which may drive future financing and growth for the company.
- Technology Integration Progress: Cyclerion will leverage its neuropsychiatric and clinical development expertise to strengthen the integration with Medsteer's technology, with device integration expected to be completed in 2026, laying a solid foundation for subsequent clinical trials.
See More
Cyclerion Therapeutics Expands Collaboration with Medsteer, Shares Surge 44.2%
- Significant Stock Surge: Cyclerion Therapeutics shares rose 44.2% to $1.99 in pre-market trading, reflecting strong market confidence in the company's expanded strategic collaboration with Medsteer, indicating positive investor sentiment towards future growth prospects.
- Deepening Strategic Collaboration: The partnership with Medsteer aims to advance the closed-loop anesthetic platform CYC-126, which is expected to accelerate the product's market entry, thereby enhancing the company's competitive edge in the anesthesia sector.
- Optimistic Market Outlook: With continuous advancements in anesthetic technology, Cyclerion's new platform is poised to meet the increasing medical demand, further driving revenue growth and strengthening its position in the healthcare industry.
- Increased Investor Confidence: The substantial stock price increase not only reflects market approval of the company's strategic direction but may also attract more investor interest, thereby supporting future financing and expansion efforts.
See More
